189 related articles for article (PubMed ID: 35408859)
21. Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis.
Hazenberg AJ; Dikkers FG; Hawkins PN; Bijzet J; Rowczenio D; Gilbertson J; Posthumus MD; Leijsma MK; Hazenberg BP
Laryngoscope; 2009 Mar; 119(3):608-15. PubMed ID: 19235761
[TBL] [Abstract][Full Text] [Related]
22. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
23. Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I.
Raimondi S; Guglielmi F; Giorgetti S; Di Gaetano S; Arciello A; Monti DM; Relini A; Nichino D; Doglia SM; Natalello A; Pucci P; Mangione P; Obici L; Merlini G; Stoppini M; Robustelli P; Tartaglia GG; Vendruscolo M; Dobson CM; Piccoli R; Bellotti V
J Mol Biol; 2011 Apr; 407(3):465-76. PubMed ID: 21296086
[TBL] [Abstract][Full Text] [Related]
24. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis.
Rader DJ; Gregg RE; Meng MS; Schaefer JR; Zech LA; Benson MD; Brewer HB
J Lipid Res; 1992 May; 33(5):755-63. PubMed ID: 1619367
[TBL] [Abstract][Full Text] [Related]
25. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene.
Yazaki M; Liepnieks JJ; Yamashita T; Guenther B; Skinner M; Benson MD
Kidney Int; 2001 Nov; 60(5):1658-65. PubMed ID: 11703582
[TBL] [Abstract][Full Text] [Related]
26. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I.
Persey MR; Booth DR; Booth SE; van Zyl-Smit R; Adams BK; Fattaar AB; Tennent GA; Hawkins PN; Pepys MB
Kidney Int; 1998 Feb; 53(2):276-81. PubMed ID: 9461086
[TBL] [Abstract][Full Text] [Related]
27. Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells.
Arciello A; De Marco N; Del Giudice R; Guglielmi F; Pucci P; Relini A; Monti DM; Piccoli R
J Cell Mol Med; 2011 Dec; 15(12):2652-63. PubMed ID: 21306558
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein A-I amyloidogenic variant L174S, expressed and isolated from stably transfected mammalian cells, is associated with fatty acids.
Monti DM; Di Gaetano S; Del Giudice R; Giangrande C; Amoresano A; Monti M; Arciello A; Piccoli R
Amyloid; 2012 Mar; 19(1):21-7. PubMed ID: 22295944
[TBL] [Abstract][Full Text] [Related]
29. Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity.
Ramella NA; Schinella GR; Ferreira ST; Prieto ED; Vela ME; Ríos JL; Tricerri MA; Rimoldi OJ
PLoS One; 2012; 7(8):e43755. PubMed ID: 22952757
[TBL] [Abstract][Full Text] [Related]
30. mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression.
Georgila K; Gounis M; Havaki S; Gorgoulis VG; Eliopoulos AG
Metabolism; 2020 Apr; 105():154186. PubMed ID: 32084429
[TBL] [Abstract][Full Text] [Related]
31. Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I.
Wong YQ; Binger KJ; Howlett GJ; Griffin MD
FEBS Lett; 2012 Jun; 586(13):1754-8. PubMed ID: 22609356
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid A protein amyloidosis.
Elliott-Bryant R; Cathcart ES
Clin Immunol Immunopathol; 1997 Oct; 85(1):104-8. PubMed ID: 9325076
[TBL] [Abstract][Full Text] [Related]
33. New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis.
Colombat M; Aldigier JC; Rothschild PR; Javaugue V; Desport E; Frouget T; Goujon JM; Rioux-Leclercq N; Quellard N; Rerolle JP; Paraf F; Beugnet C; Tiple A; Durrbach A; Samuel D; Brézin A; Bridoux F; Valleix S
Kidney Int; 2020 Jul; 98(1):195-208. PubMed ID: 32571483
[TBL] [Abstract][Full Text] [Related]
34. A study of apolipoproteins E and A-I in cutaneous amyloids.
Chang YT; Tsai SF; Wang WJ; Hong CJ; Huang CY; Wong CK
Br J Dermatol; 2001 Sep; 145(3):422-7. PubMed ID: 11531831
[TBL] [Abstract][Full Text] [Related]
35. Novel clinical manifestations and treatment of hereditary apoA-I amyloidosis: when a good protein turns bad.
Gursky O
Kidney Int; 2020 Jul; 98(1):62-64. PubMed ID: 32571494
[TBL] [Abstract][Full Text] [Related]
36. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
37. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro.
Coriu D; Dispenzieri A; Stevens FJ; Murphy CL; Wang S; Weiss DT; Solomon A
Amyloid; 2003 Dec; 10(4):215-23. PubMed ID: 14986480
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature.
Lu C; Zuo K; Lu Y; Liang S; Huang X; Zeng C; Zhang J; An Y; Wang J
Medicine (Baltimore); 2017 Sep; 96(39):e8148. PubMed ID: 28953655
[TBL] [Abstract][Full Text] [Related]
39. Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.
Perampalam P; Hassan HM; Lilly GE; Passos DT; Torchia J; Kiser PK; Bozovic A; Kulasingam V; Dick FA
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33444292
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils.
Higuchi K; Kogishi K; Wang J; Xia C; Chiba T; Matsushita T; Hosokawa M
Biochem J; 1997 Aug; 325 ( Pt 3)(Pt 3):653-9. PubMed ID: 9271085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
